We are developing an MHC-haploidentical allogeneic bone marrow transplantation model that parallels human treatment and can be used to decipher the immunologic impact of post-transplantation cyclophosphamide (PTCy). We are studying the impact of this therapy on clinical endpoints (survival, graft-versus-host disease, weight); accompanying these studies is a detailed characterization of the immunologic and histopathologic changes associated with this approach. Once the mechanisms by which PTCy prevents GVHD uncovered, we will use this understanding as a basis to explore how to refine this BMT approach clinically towards the clinical goals of further reducing graft-versus-host disease, ensuring reliable engraftment with minimal conditioning, and serving as a platform for other therapies to reduce relapse. We also are exploring the impact of PTCy on human T cells in mixed lymphocyte cultures with the goal of improving our understanding of the immunologic impact of PTCy in order to improve clinical outcomes. Lastly, we have begun a study to investigate if antigen-specific cellular therapy can be safely and effectively integrated with haplo BMT using PTCy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC011659-04
Application #
9779989
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Kanakry, Christopher G; Luznik, Leo (2018) Teaching a Young Dog New Tricks: Modifications to the Post-Transplantation Cyclophosphamide Haploidentical Transplantation Platform. Biol Blood Marrow Transplant 24:1108-1110
Kanakry, Christopher G; Coffey, David G; Towlerton, Andrea M H et al. (2016) Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamide. JCI Insight 1:
Kanakry, Christopher G; Fuchs, Ephraim J; Luznik, Leo (2016) Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol 13:10-24
Kanakry, Christopher G; O'Donnell, Paul V; Furlong, Terry et al. (2014) Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol 32:3497-505
Kanakry, Christopher G; Tsai, Hua-Ling; BolaƱos-Meade, Javier et al. (2014) Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood 124:3817-27